Hemophilia A Gene Therapy Race Intensifies With Updated Sangamo/Pfizer Data
Executive Summary
Sangamo and Pfizer released positive Phase I/II data from a cohort of patients treated with a higher dose of the gene therapy SB-525 for hemophilia A, but rivals are further ahead in development.
You may also be interested in...
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
Roche Confident Spark Therapeutics Acquisition Will Complete In First Half
US financial regulators have not been quick at reviewing Roche’s multi-billion dollar acquisition of gene therapy biotech Spark Therapeutics, but it is still on track for completion in the first half of 2019.